Mylan EPD released its biosimilar version of Nesp (darbepoetin alfa) on December 2, marking the last of three follow-on launches for the major renal anemia drug after ones from JCR Pharmaceuticals/Kissei Pharmaceutical and Sanwa Kagaku Kenkyusho/Gene Techno Science. Three biosimilars…
To read the full story
Related Article
- Mylan EPD Curbing Nesp Biosimilar Supplies amid Big Demand
May 11, 2020
- Japan’s First Biosimilars for Nesp, Forteo Hit Shelves
November 27, 2019
BUSINESS
- Lunsumio Combo Hits PIII Goal in Follicular Lymphoma: Roche
September 18, 2026
- Padcev-Keytruda Gets CHMP Nod for Expanded MIBC Use
September 18, 2026
- SanBio Eyes October Start for Akuugo Treatment
September 18, 2026
- Toho Unit to Launch Pharma-Wholesaler Payment Service
September 18, 2026
- Astellas Names Marino General Counsel, Compliance Chief
September 18, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





